Vitamin K antagonist
Rivaroxaban and other non-vitamin K antagonist oral anticoagulants in the emergency treatment of thromboembolism
9
Portable coagulometer for vitamin K-antagonist monitoring: the patients’ point of view
6
Non-vitamin K antagonist oral anticoagulants vs. vitamin-K antagonists in patients with atrial fibrillation and chronic kidney disease: a nationwide cohort study
8
Effective management of venous thromboembolism in the community: non-vitamin K antagonist oral anticoagulants
9
Strengths and weaknesses of ‘real-world’ studies involving non-vitamin K antagonist oral anticoagulants
12
Non Vitamin K Antagonist Oral Anticoagulants: Redefining the Role of the Nurse to Improve Patient Care
16
Practical and clinical considerations in assessing patients with atrial fibrillation for switching to non-vitamin K antagonist oral anticoagulants in primary care
9
Anti-inflammatory and antiplatelet effects of non-vitamin K antagonist oral anticoagulants in acute phase of ischemic stroke patients
6
Stroke prevention in the elderly atrial fibrillation patient with comorbid conditions: focus on non-vitamin K antagonist oral anticoagulants
14
Vitamin K antagonist use: evidence of the difficulty of achieving and maintaining target INR range and subsequent consequences
10
Prothrombin complex concentrate in surgical patients: retrospective evaluation of vitamin K antagonist reversal and treatment of severe bleeding
15
Non-vitamin K antagonist oral anticoagulants in adults with a Fontan circulation: are they safe
5
Vitamin K antagonist use and renal function in pre-dialysis patients
8
Implementation of non-vitamin K antagonist oral anticoagulants in daily practice: the need for comprehensive education for professionals and patients
14
Efficacy and safety of non-vitamin K antagonist oral anticoagulants compared with warfarin in patients with atrial fibrillation
9
The Results of Using Electronic Health Software for Self-Management of Vitamin K Antagonist Therapy: A Systematic Review
8
Updates in the perioperative and emergency management of non vitamin K antagonist oral anticoagulants
6
Quality of vitamin K antagonist control and outcomes in atrial fibrillation patients: a meta-analysis and meta-regression
20
Rivaroxaban versus enoxaparin/vitamin K antagonist therapy in patients with venous thromboembolism and renal impairment
8
Label Adherence for Non Vitamin K Antagonist Oral Anticoagulants in a Prospective Cohort of Asian Patients with Atrial Fibrillation
8